Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $1.95, $0.03 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $2.04 billion versus the consensus estimate of $2.07 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2022 EPS of $6.40-$6.80 vs 7.93 consensus.

• 2022 Reported Revenue Change (4.0)% - 0.0%

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.